Irinotecan
Systemic Treatments for Mesothelioma: Standard and Novel
Current Treatment Options in Oncology. 2008 Jun;9(2-3):171-9. Epub 2008 Sep 3. [Link] Kindler HL. Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA. hkindler@medicine.bsd.uchicago.edu Abstract Systemic therapy is the only treatment option for the majority of mesothelioma patients, for whom age, co-morbid medical illnesses, non-epithelial histology, and locally advanced disease often preclude surgery. For…
Read MoreA Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies
Clinical Cancer Research 13, 532-539, January 15, 2007. [Link] Eric K. Rowinsky1, Muralidhar Beeram1, Lisa A. Hammond1, Garry Schwartz2, Johann De Bono1, Baharam Forouzesh1, Quincy Chu1, Jane E. Latz3, Shengyan Hong3, William John3 and Binh Nguyen3 Authors’ Affiliations: 1 Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas; 2 Brooke Army Medical…
Read MoreEfficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma
Cancer. 2007 Jan 1;109(1):93-9. [Link] Fennell DA, Steele JP, Shamash J, Evans MT, Wells P, Sheaff MT, Rudd RM, Stebbing J. Lung and Mesothelioma Unit, Department of Medical Oncology, St Bartholomew’s Hospital, West Smithfield, London, UK. Abstract Background: Malignant pleural mesothelioma (MPM) is a rapidly progressive lethal tumor. Treatment options remain limited and the outcome…
Read MoreEpidemiologic surveillance for primary prevention of malignant mesothelioma: the Italian experience
La Medicina del Lavoro. 2005 Jul-Aug;96(4):338-46. [Link] Nesti M, Marinaccio A, Gennaro V, Gorini G, Mirabelli D, Mensi C, Merler E, Montanaro F, Musti M, Pannelli F, Romanelli A, Tumino R; ReNaM Working Group. ISPESL – National Institute for occupational safety and prevention, Occupational Medicine Department, Epidemiology Unit Rome, Italy. Abstract Background: The Italian National…
Read MoreIrinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B
Lung Cancer. 2005 Jun;48(3):423-8. Epub 2005 Feb 16. [Link] Kindler HL, Herndon JE, Zhang C, Green MR; Cancer and Leukemia Group B. University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL 60637, USA. hkindler@medicine.bsd.uchicago.edu Abstract Purpose: The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the activity…
Read More